Treatment of atrial fibrillation and atrial flutter: Part II

Cardiology in Review

Volumn 16, Issue 5, 2008, Pages 230-239

  Aronow, Wilbert S ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic drugs; Aspirin; Atrial fibrillation; Atrial flutter; Cardioversion; Pacemakers; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APRINDINE; ATENOLOL; AZIMILIDE; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; IMIPRAMINE; METOPROLOL; MEXILETINE; MORACIZINE; PHENYTOIN; PLACEBO; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TOCAINIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; XIMELAGATRAN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM THROMBOSIS; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; POLYMORPHIC VENTRICULAR TACHYCARDIA; RADIOFREQUENCY ABLATION; REVIEW; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TORSADE DES POINTES; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; UNSPECIFIED SIDE EFFECT; WOLFF PARKINSON WHITE SYNDROME; HEART PACING; PATHOPHYSIOLOGY; RISK FACTOR;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CARDIAC PACING, ARTIFICIAL; ELECTRIC COUNTERSHOCK; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; WARFARIN;

EID: 53849102084     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181723694     Document Type: Review

References (109)

1. Aronow WS, Uyeyama RR. Treatment of arrhythmias with pindolol. Clin Pharmacol Ther. 1972;13:15-22.
2. Aronow WS, Van Camp S, Turbow M, et al. Acebutolol in supraven-tricular arrhythmias. Clin Pharmacol Ther. 1979;25:149-153.
3. Aronow WS. Use of beta-adrenergic blockers in antiarrhythmic therapy. Pract Cardiol. 1986;12:75-89.
4. Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J. 1985;110:913-922.
5. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol. 1989;63:1046-1051.
6. Aronow WS, Landa D, Plasencia G, et al. Verapamil in atrial fibrillation and atrial flutter. Clin Pharmacol Ther. 1979;26:578-583.
7. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987;106:503-506.
8. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991;114:573-575.
9. Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: which is the preferred treatment? Drugs Aging. 1991;1:98-103.
10. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225-227.
11. Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation. 1999;99:2765-2770.
12. Galun E, Flugelman MY, Glickson M, et al. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest. 1991;99:1038-1040.
13. Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation. 2000;102:2503-2508.
14. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378-1382.
15. Roth A, Harrison E, Milani G, et al. Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73:316-324.
16. Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest. 1983;83: 491-499.
17. Farshi R, Kistner D, Sarma JSM, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-310.
18. Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986;57:124-127.
19. Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76: 47-50.
20. Ezekowitz MD. Maintaining sinus rhythm: making treatment better than the disease. N Engl J Med. 2007;357:1039-1041.
21. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357:987-989.
22. Michelson EL. Clinical perspectives in management of Wolff-Parkinson- White syndrome. Part 2: diagnostic evaluation and treatment strategies. Mod Concepts Cardiovasc Dis. 1989;58:49-54.
23. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by ra-diofrequency current. N Engl J Med. 1991;324:1605-1611.
24. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction. Final results of a prospective, multicenter clinical trial. Circulation. 1999;99:262-270.
25. Morris JJ Jr, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation: immediate and long-term results and selection of patients. Ann Intern Med. 1966;65:216-231.
26. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1265.
27. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation. Comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101:1282-1287.
28. Feld GK, Chen P-S, Nicod P, et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol. 1990;66:378-383.
29. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117:141-150.
30. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiar-rhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997;127:281-284.
31. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;329:406-412.
32. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a Class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 1997;29:385-390.
33. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865.
34. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-136.
35. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999;340:1849-1854.
36. Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354-1361.
37. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:S579-S589.
38. Fatkin D, Kuchar DL, Thorburn CW, et al. Transesophageal echocardio-graphy before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-316.
39. Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study. Circulation. 1994;89:2509-2513.
40. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-1420.
41. Grimm RA, Leung DY, Black IW, et al. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J. 1995;130: 174-176.
42. Silverman DI, Manning WJ. Strategies for cardioversion of atrial fibrillation - time for a change? N Engl J Med. 2001;344:1468-1469.
43. Seto TB, Taira DA, Manning WJ. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis. J Am Soc Echocardiogr. 1999;12:508-516.
44. Coplen SE, Antmann EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990;82: 1106-1116.
45. Aronow WS, Mercando AD, Epstein S, et al. Effect of quinidine or procainimide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol. 1990;66:423-428.
46. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932-1939.
47. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558-563.
48. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-920.
49. Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized, double-blind, placebo controlled study. J Am Coll Cardiol. 2000;36:139-146.
50. Pritchett ELC, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J Am Coll Cardiol. 2000;36:794-802.
51. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20:527-532.
52. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270:1589-1595.
53. Greene HL, for the CASCADE Investigators. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol. 1993;72:F70-F74.
54. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13:442-449.
55. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol. 1994;74:267-270.
56. Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol. 1996;78(Suppl 8A):S27-S34.
57. Hohnloser SH, Cuck K-H, Lilienthal J, for the PIAF Investigators. Rhythm or rate control in atrial fibrillation - pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet. 2000;356: 1789-1794.
58. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
59. Freudenberger RS, Wilson AC, Kostis JB, for the AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am J Cardiol. 2007;100:247-252.
60. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
61. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation. Data of the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 2005;46:1298-1306.
62. Al-Khatib SM, Shaw LK, Lee KL, et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? Am J Cardiol. 2004;94:797-800.
63. Israel CW, Gronefeld G, Ehrlich JR et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. Implications for optimal patient care. J Am Coll Cardiol. 2004;43:47-52. Roy D, Talajic M, Nattel S, et al; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358:2667-2677.
64. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
65. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
66. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
67. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
68. Peterson P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175-179.
69. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med. 1990;322:863-868.
70. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527-539.
71. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:345-355.
72. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
73. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet. 1994;343:687-691.
74. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen atrial fibrillation, aspirin, and anticoagulation study. Arch Intern Med. 1998;158: 1513-1521.
75. Aronow WS, Ahn C, Kronzon I, et al. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000;85:1033-1035.
76. Aronow WS, Ahn C, Kronzon I, et al. Incidence of new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc. 1999;47:366-368.
77. The SPAF III. Writing Comittee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: stroke prevention in atrial fibrillation III study. JAMA. 1998;279:1273-1277.
78. Mant J, Hobbs FDR, Fletcher K, on behalf of the BAFTA Investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet. 2007; 370:493-503.
79. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
80. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-752.
81. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: an executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48:854-906. 81a. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:546S-592S.
82. Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Heart Dis. 2000;2:151-167.
83. Singer DE, Go AS. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2001;17:131-147.
84. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987;317:669-674.
85. Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham study. JAMA. 1985;254:3449-3453.
86. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822-827.
87. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:1423-1424.
88. Nieuwlaat R, Olsson SB, Lip GYH, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: the Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153:1006-1012.
89. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
90. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521-523.
91. Aronow WS, Ahn C, Kronzon I, et al. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2384 older persons. Am J Cardiol. 1999;84: 468-469.
92. Planning and Steering Committees for AFFIRM Study. Atrial fibrillation follow up investigation of rhythm management: the AFFIRM study design. Am J Cardiol. 1997;79:1198-1202.
93. Aronow WS, Ahn C, Kronzon I, et al. Risk factors for new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation. Am J Cardiol. 1998;82:119-121.
94. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol. 1989;63:366-367.
95. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687-1691.
96. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
97. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximel-agatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003; 362:1691-1698.
98. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with non-valvular atrial fibrillation. JAMA. 2005;293:690-698.
99. Connolly SJ, Eikelboom J, O'Donnell M, et al. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation. 2007;116:449-455.
100. Granada J, Uribe W, Chyou P-H, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36: 2242-2246.
101. Mehta D, Baruch L. Thromboembolism following cardioversion of common atrial flutter. Chest. 1996;110:1001-1003.
102. Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol. 1997;30:1506-1511.
103. Grimm RA, Stewart WJ, Arheart KL, et al. Left atrial appendage "stunning" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J Am Coll Cardiol. 1997;29:582-589.
104. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, et al. Pharm-acologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84:R147-R151.
105. Orlando J, Del Vicario M, Aronow WS. High reversion of atrial flutter to sinus rhythm after atrial pacing in patients with pulmonary disease. Chest. 1977;71:580-582.
106. Saxon LA, Kalman JM, Olgin JE, et al. Results of radiofrequency catheter ablation for atrial flutter. Am J Cardiol. 1996;77:1014-1016.
107. Poty H, Saoudi N, Aziz AA, et al. Radiofrequency of catheter ablation of type 1 atrial flutter: prediction of late success by electrophysiological criteria. Circulation. 1995;92:1389-1392.
108. Channamsetty V, Aronow WS, Sorbera C, et al. Efficacy of radiofrequency catheter ablation in treatment of elderly patients with supraventricular tachyarrhythmias and ventricular tachycardia. Am J Ther. 2006;13:513-515.
109. Calkins H, Canby R, Weiss R, et al. Results of catheter ablation of typical atrial flutter. Am J Cardiol. 2004;94:437-442.